Atorvastatin Calcium (Lipitor) Drug Profile and Competitive Landscape 2026
Atorvastatin Calcium (Lipitor): Competitive Landscape 2026
Atorvastatin Calcium (Lipitor) is a small molecule HMG-CoA reductase inhibitor originated by Pfizer Inc. and first approved in December 1996. It carries 19 indications in the database and 4 recorded deals spanning from 1997 to 2021.
Atorvastatin Calcium (Lipitor): Drug Overview and Status
Atorvastatin Calcium, marketed as Lipitor, is a small molecule drug originated by Pfizer Inc. First approved on December 17, 1996, it is one of the earliest approved statins and has maintained approved global development status for nearly three decades. Active commercialization is now distributed across Aspen Pharmacare Australia Pty Ltd., HealthBioAI, and Upjohn Manufacturing Ireland Unlimited Co.
The drug’s primary target is HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), the rate-limiting enzyme in the mevalonate biosynthetic pathway. By competitively inhibiting HMGCR, atorvastatin reduces hepatic cholesterol biosynthesis and secondarily upregulates LDL receptor expression, increasing clearance of circulating LDL particles and lowering plasma LDL-cholesterol.
The database records 19 total indications. Primary approved cardiovascular indications include Heart Failure, Angina Pectoris, and Myocardial Infarction. Research-stage indications inferred from patent data include Alzheimer’s Disease, cerebral stroke recurrence, rheumatoid arthritis, atherosclerosis, osteoporosis, and combination metabolic syndrome applications.
Active organizations include Aspen Pharmacare Australia Pty Ltd., HealthBioAI, and Upjohn Manufacturing Ireland Unlimited Co. Deal history includes co-marketing with Warner-Lambert (1997), co-development with Astellas (2000), a generic licensing deal with Sanofi (2011), and a co-promotion agreement between Astellas and Viatris in Japan (2021).
HMGCR Target Competitors: Statins and Combination Products
Four competitor drugs were identified on the same HMGCR target and cardiovascular disease axis, ranging from single-agent statins (Rosuvastatin Calcium, approved 2002) to fixed-dose combinations pairing statins with antihypertensive agents approved as recently as 2019.
Competitor Drugs by First Approval Date (HMGCR Target)
Atorvastatin Calcium holds the earliest approval date (1996) among the four retrieved HMGCR competitors; two fixed-dose combinations entered the market after 2015.
↗ Click bars to exploreAtorvastatin Calcium Deal Activity Timeline (1997–2021)
Four deals span 24 years, from an early co-marketing partnership in 1997 through a Japan co-promotion agreement in 2021, reflecting the full commercial lifecycle of a mature blockbuster.
↗ Click bars to exploreAtorvastatin Calcium Indications: Cardiovascular and Beyond
The database records 19 total indications for Atorvastatin Calcium. Approved primary indications are cardiovascular, while patent data reveals a broader exploratory pipeline spanning neurological, immunological, and metabolic disease areas.
Heart Failure
Heart Failure is listed as an approved primary cardiovascular indication for Atorvastatin Calcium in the database. As an HMG-CoA reductase inhibitor, atorvastatin’s LDL-lowering mechanism and pleiotropic cardioprotective effects underpin its use in this indication. It is one of three explicitly listed approved cardiovascular indications alongside Angina Pectoris and Myocardial Infarction.
CardiovascularMyocardial Infarction
Myocardial Infarction is recorded as an approved primary indication for Atorvastatin Calcium in the structured database. The drug’s mechanism of reducing circulating LDL cholesterol through HMGCR inhibition is directly relevant to reducing atherosclerotic cardiovascular event risk. This indication is part of the core approved cardiovascular portfolio alongside Heart Failure and Angina Pectoris.
CardiovascularAlzheimer’s Disease
Alzheimer’s Disease is an exploratory indication inferred from patent WO1999038498A1, which describes methods for treating Alzheimer’s using triglyceride-lowering agents, optionally combined with cholesterol-lowering agents including statins. This patent is currently inactive. R&D teams in CNS may find mechanistic rationale in atorvastatin’s pleiotropic effects for revisiting statin-class activity in neuroinflammation.
NeurologyRheumatoid Arthritis
Rheumatoid arthritis and inflammatory joint diseases are referenced in patent US20140127295A1 (CELLWORKS GRP INC), which describes a multi-compound composition including atorvastatin for this indication. Patent WO2002024194A3 (NOVIMMUNE SA) further supports immunomodulatory applications of statins via MHC class II and CD40 modulation. Both patents are currently inactive in the dataset.
ImmunologyOrganizations in the Atorvastatin Calcium Ecosystem
Pfizer Inc. is the originator of Atorvastatin Calcium (Lipitor), with active commercialization now distributed across Aspen Pharmacare Australia Pty Ltd., Upjohn Manufacturing Ireland Unlimited Co., and HealthBioAI. The patent assignee landscape is highly fragmented across 25 entities, with only two holding active patents.
Top Patent Assignees by Filing Count (Atorvastatin Calcium)
↗ Click bars to explorePfizer Inc.
Pfizer Inc. is the originator of Atorvastatin Calcium (Lipitor), which received its first approval on December 17, 1996. Pfizer co-marketed Lipitor with Warner-Lambert in 1997 and later partnered with Sanofi in 2011 for generic Lipitor distribution following patent expiry. Pfizer does not appear as an active patent assignee among the 20 retrieved patents, confirming a full exit from IP protection for this molecule.
United StatesArch Pharmalabs Ltd
Arch Pharmalabs Ltd holds patent IN279634B, one of only two active patents in the Atorvastatin Calcium dataset. This patent covers a process for preparation of a key atorvastatin intermediate (4-fluoro compound) with stringent impurity specifications, filed 2008 and published 2017. This active synthesis patent retains relevance for API manufacturers operating in the post-exclusivity market.
IndiaStrategic Outlook for Atorvastatin Calcium (Lipitor)
With 18 of 20 retrieved patents inactive and Pfizer absent from the active patent assignee list, the strategic landscape for Atorvastatin Calcium is defined by formulation innovation, combination therapy, and regional brand monetization rather than molecular exclusivity.
Combination Therapy as the Primary Innovation Vector
The competitive landscape shows a clear market shift toward statin-based fixed-dose combinations, with Rosuvastatin/Nebivolol (2019) and Pitavastatin/Valsartan (2015) representing newer, IP-protected entrants on the HMGCR axis. Multiple retrieved patents explore atorvastatin in combination with ezetimibe (CN103340852A), nicotinic acid (IN4400CHENP2009A), voglibose (CN103110622A), and omega-3 fatty acids (KR101515492B1, active). BD and R&D teams should evaluate fixed-dose combination strategies as the principal route to IP-protected positioning in the statin class.
Japan Market as Active Commercial Battleground
Two of the four recorded Lipitor deals involve Japan-specific activity: the Astellas co-development agreement in 2000 and the Astellas-Viatris co-promotion agreement in 2021. This sustained 21-year commercial engagement in Japan signals that the branded Lipitor product retains relevance in this market long after patent expiry elsewhere. BD professionals assessing Asia-Pacific opportunities should examine the Astellas-Viatris co-promotion model as a reference for mature brand monetization in the region.
Atorvastatin Patent Position Summary
| Total Patents | 20 |
| Active Patents | 2 |
| Key Assignee | Warner Lambert Co LLC |
| Earliest Filing | 1999 |
| Primary Themes | Synthesis intermediates, polymorphic forms, combination formulation, novel indications |
Atorvastatin Calcium vs Rosuvastatin Calcium: HMGCR Comparator
Click any row to explore further in PatSnap Eureka.
| Dimension | Atorvastatin Calcium (Lipitor) | Rosuvastatin Calcium |
|---|---|---|
| Drug Type | Small molecule | Small molecule |
| Primary Target | HMGCR (HMG-CoA Reductase) | HMGCR (HMG-CoA Reductase) |
| Mechanism of Action | HMG-CoA reductase inhibitor; reduces hepatic cholesterol biosynthesis; upregulates LDL receptor expression | HMG-CoA reductase inhibitor; single-agent statin |
| Product Class | Single agent statin | Single agent statin |
| First Approved | 1996-12-17 | 2002-11-06 |
| Global Status | Approved | Approved |
| Key Indications | Heart Failure, Angina Pectoris, Myocardial Infarction (19 total in database) | HMGCR target; cardiovascular disease axis |
| Originator | Pfizer Inc. | Not specified in retrieved records |
| Active Organizations | Aspen Pharmacare Australia; HealthBioAI; Upjohn Manufacturing Ireland Unlimited Co. | Not specified in retrieved records |
| Active Patents (Retrieved) | 2 of 20 retrieved patents active | Not specified in retrieved records |
Frequently Asked Questions: Atorvastatin Calcium (Lipitor)
Atorvastatin Calcium (brand name Lipitor) is a small molecule HMG-CoA reductase inhibitor. It works by competitively inhibiting HMGCR, the rate-limiting enzyme in the mevalonate biosynthetic pathway. This reduces hepatic cholesterol biosynthesis and secondarily upregulates LDL receptor expression on hepatocyte surfaces, leading to increased clearance of circulating LDL particles and reduced plasma LDL-cholesterol levels.
The database records 19 total indications for Atorvastatin Calcium. The three explicitly listed approved primary cardiovascular indications are Heart Failure, Angina Pectoris, and Myocardial Infarction. Additional research-stage indications inferred from patent data include Alzheimer’s Disease, cerebral stroke recurrence, rheumatoid arthritis, atherosclerosis, osteoporosis, and combination metabolic syndrome applications.
Atorvastatin Calcium (Lipitor) was originated by Pfizer Inc. and first approved on December 17, 1996. Warner-Lambert Co. was a co-originator and co-marketing partner from 1997. Active organizations in the current dataset include Aspen Pharmacare Australia Pty Ltd., HealthBioAI, and Upjohn Manufacturing Ireland Unlimited Co. In Japan, Astellas Pharma and Viatris Inc. jointly promote Lipitor tablets under a co-promotion agreement signed in March 2021.
Four competitor drugs were identified on the same HMGCR target and cardiovascular disease axis in the database: Rosuvastatin Calcium (approved 2002-11-06), Pitavastatin Calcium/Valsartan (approved 2015-02-25), and Rosuvastatin Calcium/Nebivolol Hydrochloride (approved 2019-08-30). Rosuvastatin Calcium is the most direct single-agent comparator. Two competitors are fixed-dose combination products pairing a statin with an antihypertensive agent.
Four deals are recorded in the database spanning 1997 to 2021. These include: a co-marketing agreement between Warner-Lambert and Pfizer (1997); a co-development agreement between Warner-Lambert and Astellas Pharma (2000); a generic licensing and distribution deal between Pfizer and Sanofi (2011); and a co-promotion agreement between Astellas Pharma and Viatris Inc. for Lipitor tablets in Japan (2021). No financial values were disclosed in any of the retrieved deal records.
A total of 20 patents were retrieved in the dataset. Only 2 are recorded as Active: IN279634B (ARCH PHARMALABS LTD), covering a synthesis intermediate process, and KR101515492B1 (KUHNIL PHARMA CO LTD), covering an omega-3 fatty acid/statin oral combination formulation. The remaining 18 patents are inactive, consistent with atorvastatin’s status as a mature, off-patent molecule. Pfizer Inc. and Warner-Lambert Co. LLC do not hold any active patents in the retrieved dataset.
Data and insights on this page are based on a limited patent, clinical, and biopharma intelligence dataset and are for reference only.